Resverlogix Corp. announced that it has entered into a licensing agreement with Medison Pharma Ltd. for the company's lead therapeutic candidate, apabetalone (RVX-208), in Israel and the Palestine Authority. Apabetalone is currently in development for the treatment of high- risk cardiovascular disease (CVD) in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD), and potential expanded indications. Under the terms of the agreement, Medison has the exclusive rights to distribute and market apabetalone in Israel. Resverlogix is eligible to receive from Medison, ascending double digit royalties based on future net sales of the product in the region. If certain sales milestones are reached total royalty payments are estimated to potentially reach in excess of $100 million over the entire patent life in the region. Medison will be responsible for all regulatory, sales and marketing costs for apabetalone in the Israel region.